⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224194 | 1.00 | — | — | |
| SCHEMBL15811681 | 0.85 | — | — | |
| SCHEMBL325804 | 0.85 | TSHR (0.40) | — | |
| SCHEMBL17664807 | 0.85 | — | — | |
| SCHEMBL15628682 | 0.82 | TSHR (0.38) | — | |
| SCHEMBL13877207 | 0.82 | TSHR (0.38) | — | |
| SCHEMBL10136491 | 0.82 | — | — | |
| SCHEMBL223185 | 0.81 | TSHR (0.33) | — | |
| SCHEMBL10100324 | 0.81 | TSHR (0.33) | — | |
| SCHEMBL19443306 | 0.81 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2010036407-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010011748-A2 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-2080779-A1 | POLYMERIC DERIVATIVE OF NUCLEIC ACID METABOLIC ANTAGONIST | Nippon Kayaku Kabushiki Kaisha (JP) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |